Weekly Recap: 10 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Lilly's newest acquisition, Visby Medical's $65M Financing Round, and Mark Cuban's Cost Plus Drug collab with 9amHealth

NEW YORK, June 20, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

1. Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. Lilly shares our vision, and we believe their global research, clinical, regulatory and commercial capabilities will help to accelerate the development of our medicines."
2. Shasqi Publishes Landmark Study in Clinical Cancer Research: First-in-Human Use of Click Chemistry Unlocks New Opportunities for Targeted Cancer Therapies Shasqi's Click Activated Protodrugs Against Cancer (CAPAC®) platform is a pre-targeting technology composed of a tumor binding agent and a protodrug. Administered sequentially, these components are designed to only click with each other via a click chemistry reaction occurring directly at the tumor site. This releases high concentrations of cancer drugs at the tumor while sparing healthy tissues.
3. Visby Medical™ Raises up to $65 Million in New Financing Round to Accelerate Launch of Groundbreaking At-Home Sexually Transmitted Infections (STI) Test
   Visby Medical's at-home Women's Sexual Health Test is the first single-use, disposable PCR diagnostic that delivers results within 30 minutes through a connected smartphone app. Upon receiving positive results, users are seamlessly connected with telemedicine providers for consultation and treatment, enhancing healthcare accessibility and privacy. The product will be available starting July 2025 through major direct-to-consumer channels.
4. Neuspera Medical Receives FDA Approval for First Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence "FDA approval of Neuspera's iSNM system represents a major advancement for millions of patients with UUI," said Dr. Howard Goldman, vice-chairman of Urology at the Cleveland Clinic. "For too long, patients have had to weigh the benefits of SNM therapy against real concerns about complications related to implanted batteries and the need for surgeries to replace it. Neuspera's integrated system provides symptom relief without these additional burdens."
5. Arbonne Unveils Innovative Plant-Powered Hair Care Collection Fueled by Scalp Science and Clinical Results Powered by purposeful, performance-driven ingredients—like Green Coffee Oil, Pea Peptide, Snow Mushroom, Argan, Avocado, and Squalane—each product is designed to support scalp and hair health while delivering visible results. All formulas are dermatologist-tested, vegan, cruelty-free, and crafted without over 2,000 ingredients Arbonne chooses not to include in its product development process.
6. Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals This supply agreement reflects the shared vision of the two companies to accelerate innovation in the radiopharmaceutical field as the demand for diagnostic and therapeutic isotopes continues to grow. The close proximity of Ratio's new manufacturing facility in Utah, just miles from Nusano's operations, will streamline the logistics involved in scale-up and delivery.
7. U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
   "ANDEMBRY, the first monoclonal antibody discovered and developed entirely by CSL, offers people living with this life-threatening condition long-term control over their disease along with a convenient administration method," said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. "ANDEMBRY underscores our long-standing and enduring commitment to better the lives of the patients we serve, including those suffering with HAE."
8. Mark Cuban Cost Plus Drug Company, PBC and 9amHealth Join Forces to Expand Access to Affordable Obesity Care This collaboration brings together Cost Plus Drugs' groundbreaking transparent pricing model and 9amHealth's high-touch, at a time where patient demand and rising medical costs have come to a head. Employees will now have access to low-cost, high-quality medications through Cost Plus Drugs, alongside 9amHealth's expert Care Team of Obesity Medicine physicians, endocrinologists, and cardiometabolic specialists—all available without long waits or costly appointments.
9. Adona Medical Completes Enrollment in First-in-Human Trial for Novel Interatrial Shunt for Patients With Heart Failure The company's chronically-adjustable interatrial shunt with integrated bi-atrial pressure monitoring was successfully implanted in 10 patients with heart failure with 100% procedural success. All patients had their shunt diameters successfully adapted both larger and smaller relative to an initial configuration, with the impact of shunt size on the acute effects of the therapy noted.
10. FDA Expands Indication for Levita Magnetics' Magnetic Surgical System with MARS® for Minimally Invasive Bariatric and Hiatal Hernia Repair The FDA clearance enables clinicians to use the MARS system's Dynamic Magnetic Positioning™ technology to retract the liver and enhance visibility and access during hiatal hernia repairs. This approval offers an innovative, less invasive option for abdominal surgery and paves the way for broader adoption of the technology across hospitals and ambulatory surgical centers nationwide.

For more news like this, check out all of the latest health-related releases from PR Newswire.

Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:

• Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.
• Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.
• Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.
• Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

SOURCE PR Newswire